secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0001070081-24-000026
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics sells Rare Pediatric Disease PRV for $150 million cash
-----------------------------------------------------------------------

- Sale price of $150 million payable in cash upon closing to an affiliate of a large pharmaceutical company.
- PRV was awarded on November 13, 2024 with FDA approval of KEBILIDI (eladocagene exuparvovec-tneq) for AADC deficiency.
- Transaction subject to customary closing conditions including expiration of HSR Act waiting period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000026/0001070081-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000026/tmb-20241126x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer